Special Issue "New Innovations in Biomedical Engineering"

A special issue of Medicines (ISSN 2305-6320).

Deadline for manuscript submissions: closed (30 April 2018).

Special Issue Editor

Guest Editor
Prof. Dr. Gerhard Litscher

TCM Research Center Graz, Research Unit for Complementary and Integrative Laser Medicine, and Research Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine, the Medical University of Graz, Auenbruggerplatz 39, 8036 Graz, Austria
Website | E-Mail
Phone: +436641140879
Fax: +43 316 385 13908
Interests: evidence-based complementary medicine; integrative medicine; laser medicine; high-tech acupuncture; neuromonitoring

Special Issue Information

Dear Colleagues,

Biomedical Engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes. Biomedical Engineering researchers bring their skills to a broad range of fields ranging from Clinical Engineers managing all aspects of the health technology lifecycle; to Engineers in industry developing and manufacturing medical devices; and Rehabilitation Engineers taking lead roles as front-line clinicians in the assessment, design, and manufacture of assistive technology for people with disabilities.

This Special Issue is open to manuscripts on all types of biomedical engineering. Theoretical, animal experimental studies, investigations in healthy volunteers, short reports, letters to editors, study designs and clinical studies, and case reports and photo essays are welcome.

We look forward to your valuable manuscript. Together with the managing editorial team from Medicines, we will do our best to support you by publishing your important data.

Prof. DDr. Gerhard Litscher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

View options order results:
result details:
Displaying articles 1-4
Export citation of selected articles as:

Review

Jump to: Other

Open AccessReview
How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology
Received: 25 January 2018 / Revised: 12 February 2018 / Accepted: 22 February 2018 / Published: 26 February 2018
Cited by 2 | PDF Full-text (531 KB) | HTML Full-text | XML Full-text
Abstract
The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers with [...] Read more.
The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers with a potential application in the management of patients with brain tumors. Data were collected through a review of the existing English literature performed on Scopus, MEDLINE, MEDLINE in Process, EMBASE, and/or Cochrane Central Register of Controlled Trials: all available basic science and clinical papers relevant to address the above-stated research question were included and analyzed in this study. Based on the results of this systematic review we can conclude that: (1) the advances in nanotechnology and bioengineering are supporting tremendous efforts in optimizing the methods for genomic, epigenomic and proteomic profiling; (2) a successful translational approach is attempting to identify a growing number of biomarkers, some of which appear to be promising candidates in many areas of neuro-oncology; (3) the designing of Randomized Controlled Trials will be warranted to better define the prognostic value of those biomarkers and biosignatures. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
Figures

Graphical abstract

Open AccessReview
Current and Future Applications of Biomedical Engineering for Proteomic Profiling: Predictive Biomarkers in Neuro-Traumatology
Received: 31 December 2017 / Revised: 29 January 2018 / Accepted: 30 January 2018 / Published: 5 February 2018
Cited by 4 | PDF Full-text (693 KB) | HTML Full-text | XML Full-text
Abstract
This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers in patients with traumatic brain injury (TBI), a critical worldwide health problem with an estimated 10 billion people affected annually worldwide. Data were collected [...] Read more.
This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers in patients with traumatic brain injury (TBI), a critical worldwide health problem with an estimated 10 billion people affected annually worldwide. Data were collected through a review of the existing English literature performed on Scopus, MEDLINE, MEDLINE in Process, EMBASE, and/or Cochrane Central Register of Controlled Trials. Only experimental articles revolving around the management of TBI, in which the role of new devices based on innovative discoveries coming from the field of nanotechnology and biomedical engineering were highlighted, have been included and analyzed in this study. Based on theresults gathered from this research on innovative methods for genomics, epigenomics, and proteomics, their future application in this field seems promising. Despite the outstanding technical challenges of identifying reliable biosignatures for TBI and the mixed nature of studies herein described (single cells proteomics, biofilms, sensors, etc.), the clinical implementation of those discoveries will allow us to gain confidence in the use of advanced neuromonitoring modalities with a potential dramatic improvement in the management of those patients. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
Figures

Graphical abstract

Other

Jump to: Review

Open AccessPerspective
Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives
Received: 1 January 2018 / Revised: 14 February 2018 / Accepted: 20 February 2018 / Published: 25 February 2018
Cited by 6 | PDF Full-text (1072 KB) | HTML Full-text | XML Full-text
Abstract
The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on [...] Read more.
The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on biomedical engineering (microdialysis and proteomics, biochip analysis, non-invasive impedance spectroscopy, etc.) are introduced at a rapid speed in clinical practice: this article primarily aims to highlight how such platforms will advance our understanding of the pathological basis of neurological diseases. An overview of the clinical challenges and regulatory hurdles facing the introduction of such platforms in clinical practice, as well as their potential impact on patient management, will complement the discussion on foreseeable theranostic perspectives. Indeed, the techniques outlined in this article are revolutionizing how we (1) identify biomarkers that better define the diagnostic criteria of any given disease, (2) develop research models, and (3) exploit the externalities coming from innovative pharmacological protocols (i.e., those based on monoclonal antibodies, nanodrugs, etc.) meant to tackle the molecular cascade so far identified. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
Figures

Graphical abstract

Open AccessMeeting Report
Report from the BIT’s 1st Annual World Congress of Biomedical Engineering Held in Xi’an, China, 9–11 November 2017
Received: 14 November 2017 / Revised: 14 November 2017 / Accepted: 14 November 2017 / Published: 16 November 2017
Cited by 1 | PDF Full-text (1721 KB) | HTML Full-text | XML Full-text
Abstract
We are delighted to present within this meeting report the abstracts of the “BIT’s 1st World Congress of Biomedical Engineering 2017” which has been hold in Xi’an in China [...] Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
Figures

Figure 1

Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top